Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis

INTRODUCTION: Nonsmall cell lung cancer accounts for approximately 80% of all lung cancers, and approximately 75% of cases are diagnosed in the middle and late stages of disease. Unfortunately, limited treatment does not improve the prognosis of advanced disease. Monoclonal antibodies targeting prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xiaoying, Roudi, Raheleh, Chen, Shangya, Fan, Bin, Li, Hong Jin, Zhou, Min, Li, Xin, Li, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
3600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682790/
https://www.ncbi.nlm.nih.gov/pubmed/29095271
http://dx.doi.org/10.1097/MD.0000000000008407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682790/
https://www.ncbi.nlm.nih.gov/pubmed/29095271
http://dx.doi.org/10.1097/MD.0000000000008407

Ejemplares similares